After years of speculation, Qiagen N.V. (NYSE:QGEN) has finally found its buyer. The life sciences firm agreed to a 10.8 billion euros (around $12.11 billion) all-cash buyout from EQT AB (OTC:EQBBF) at 46.50 euros per share, delivering a 40.3% premium and suspending the 2026 outlook.
Qiagen's Supervisory Board and Managing Board unanimously endorsed the buyout, stating that transitioning to private ownership gives the business greater flexibility to invest for the long term while delivering certain, attractive cash returns to shareholders.
Premium Valuation And Consortium Backing
EQT will acquire all outstanding Qiagen shares at 46.50 euros apiece in cash, representing a 40.3% premium over Qiagen's XETRA closing price of 33.15 euros on July 8, 2026, the final session prior to media reports regarding private equity interest.
The bid also delivers a 46.9% premium over the stock's three-month volume-weighted average price of 31.66 euros through that date.
Strategic Review And Closing Terms
The parties expect the transaction to close in mid-2027.
If pending regulatory approvals delay the closing beyond 10 months from the announcement, Qiagen holds the option under the BCA to distribute an interim dividend of up to $0.47 per share.
The buyer will not deduct this distribution from the offer price. Qiagen will continue operating as an independent company under existing management until closing.
Preliminary Third-Quarter Performance
Alongside the acquisition agreement, Qiagen released preliminary third-quarter financial figures, posting net sales of $548 million and adjusted earnings per share of $0.65. Management simultaneously suspended its full-year 2026 financial outlook.
Portfolio Growth Challenges and Analyst Outlook
William Blair said Qiagen's sale has been long anticipated, following Thermo Fisher Scientific Inc.'s (NYSE:TMO) failed acquisition attempt in 2020 and years of takeover speculation.
The agreed price values Qiagen at about 15 times 2027 adjusted EBITDA, below the high-teens to low-20s multiples seen in comparable life sciences deals and Thermo Fisher's roughly 20-times offer in 2020.
While Qiagen has a strong core portfolio and is making progress in sample technologies, broad-based growth at QIAcuity and Parse has remained elusive.
Gains in some businesses have been offset by weakness elsewhere, including lower immigration-related demand for QuantiFERON TB testing.
“Against that backdrop, we view the takeout valuation as reasonable and the discount to prior transactions as warranted given Qiagen's lower relative growth profile,” analyst Matt Larew wrote.
QGEN Price Action: Qiagen shares were up 0.47% at $50.23 at the time of publication on Thursday, according to market data.
